Polymer Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Polymer Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$122K	Buy	+39,883	New	+$154K	0.01%	762

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Polymer Capital Management's RXRX Position: Q1 2026 in Review

Polymer Capital Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 39,883 shares worth $122K. The stake represents 0.01% of the portfolio and ranks #762 among its holdings.

334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Polymer Capital Management held 39,883 shares of Recursion Pharmaceuticals worth $122K as of Q1 2026.
Recursion Pharmaceuticals was a new Polymer Capital Management position in Q1 2026.
Recursion Pharmaceuticals made up 0.01% of Polymer Capital Management's portfolio in Q1 2026, its #762 holding.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Polymer Capital Management's 13F filing for Q1 2026, filed 14 May 2026.